Market Overview

Robbins Arroyo LLP: Ampio Pharmaceuticals, Inc. (AMPE) Misled Shareholders According to a Recently Filed Class Action


Shareholder rights law firm Robbins Arroyo LLP announces that purchasers
of Ampio Pharmaceuticals, Inc. (NYSE:AMPE) have filed a class action
complaint against the company's officers and directors for alleged
violations of the Securities Exchange Act of 1934 between December 14,
2017 and August 7, 2018. Ampio, a biopharmaceutical company, develops
therapies to treat prevalent inflammatory conditions in the United
States. The company is developing a drug known as Ampion to treat pain
due to osteoarthritis of the knee.

View this information on the law firm's Shareholder Rights Blog:

Ampio Accused of Using Trade Secrets to Enhance Its Product

According to the complaint, Ampio reported in an SEC filing that the
company had successfully completed a pivotal clinical trial for Ampion,
AP-003-A, and subsequently reported positive results from its AP-003-C
trial. As the U.S. Food and Drug Administration ("FDA") required two
pivotal trials in support of a Biologics License Application ("BLA") for
Ampion, Ampio, encouraged by the results, predicted Ampion would serve
as a safe and effective treatment for patients. However, on August 7,
2018, Ampio revealed that the FDA did not consider the AP-003-C trial to
be an adequate and well-controlled clinical trial. Further, the FDA
recommended that Ampio perform an additional randomized trial in order
to support a BLA. On this news, Ampio's stock price plummeted over 78%
to close at $0.61 per share on August 8, 2018.

Ampio Shareholders Have Legal Options

Concerned shareholders who would like more information about their
rights and potential remedies can contact attorney Leonid Kandinov at
(800) 350-6003,,
or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder
rights law. The firm represents individual and institutional investors
in shareholder derivative and securities class action lawsuits, and has
helped its clients realize more than $1 billion of value for themselves
and the companies in which they have invested. Sign up for our FREE
portfolio monitoring service, Stock

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!